Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Blog

Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.

Page 22

Explainer

GLP-1 and GIP Obesity Drugs: Evidence

A source-led guide to the evidence, safety limits, and unanswered questions around GLP-1 and dual GIP/GLP-1 obesity medicines.

18 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

Mounjaro hair loss: what trials show

Tirzepatide weight loss trials recorded hair loss in 4% to 5% of participants, compared with 1% on placebo.

18 Oct 2026 · PeptideMethods Editorial Team · 5 min read
Trial readouts

Tirzepatide and Smoking Aversion

A 2026 case report linked tirzepatide initiation with abrupt sensory aversion to cigarettes and two years of reported smoking abstinence.

18 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

Why Weight Loss Can Slow on Tirzepatide

A slower scale trend on tirzepatide can have several meanings. Here is what trials show, what the scale misses, and when to seek clinical review.

18 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

Diabetes Drugs and Cardiovascular Outcomes

A 93-trial network meta-analysis linked several diabetes drug classes with fewer cardiovascular events, while indirect comparisons limit treatment rankings.

18 Oct 2026 · PeptideMethods Editorial Team · 5 min read
Trial readouts

GLP-1s and Neurodegeneration Reviewed

A 2026 narrative review finds biological promise for GLP-1-related drugs in neurodegeneration, but no established disease-modifying benefit.

17 Oct 2026 · PeptideMethods Editorial Team · 5 min read
Trial readouts

GLP-1 Use in Serious Mental Illness

A 218,043-person retrospective cohort linked GLP-1 use with lower cardiovascular event and death risks in serious mental illness.

17 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

MASLD and MASH Drug Review

A 2026 narrative review separates approved MASH therapies from emerging candidates, including tirzepatide, while warning against cross-trial rankings.

17 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

Retatrutide Adverse Effects Online

A 2026 retatrutide social media study mapped self-reported symptoms but could not verify products, incidence, or causation.

17 Oct 2026 · PeptideMethods Editorial Team · 5 min read
Trial readouts

GLP-1 Safety Knowledge: Student Survey

A Saudi pharmacy-student survey found a mean GLP-1 safety knowledge score of 7.6 out of 17, with a 26.5% response rate.

17 Oct 2026 · PeptideMethods Editorial Team · 5 min read
Trial readouts

GLP-1 Use Before Bariatric Surgery

An editorial highlights a matched cohort linking prior GLP-1 or tirzepatide use with fewer early cardiorenal events after surgery.

17 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

Semax Glaucoma Cohort Readout

A 50-patient glaucoma surgery cohort found a visual-field signal with bundled physiotherapy, but it could not isolate an effect of Semax.

17 Oct 2026 · PeptideMethods Editorial Team · 4 min read